Related Experiment Video
Updated: Jun 24, 2025
09:43
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
8.1K
Brainstem Gliomas With Isocitrate Dehydrogenase Mutation: Natural History, Clinical-Radiological Features, Management
Changcun Pan1, Mingxin Zhang1, Xiong Xiao1
1Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing , China.
Neurosurgery
|June 11, 2024
Summary
Isocitrate dehydrogenase (IDH)-mutant brainstem gliomas (BSG-IDH mut) are a distinct group with unique features and a better prognosis than other brainstem gliomas. Further research is needed to optimize treatment strategies for this rare condition.
Area of Science:
- Neuro-oncology
- Molecular Pathology
- Clinical Neurology
Background:
- Brainstem gliomas (BSG) represent a challenging group of central nervous system tumors.
- Isocitrate dehydrogenase (IDH)-mutant BSG (BSG-IDH mut) constitute a specific molecular subtype with potentially distinct clinical behaviors.
- Understanding the characteristics of BSG-IDH mut is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the clinical, radiological, and pathological features of BSG-IDH mut.
- To analyze treatment options and long-term outcomes for patients with BSG-IDH mut.
- To identify prognostic factors and potential therapeutic targets in this rare glioma subtype.
Main Methods:
- Retrospective analysis of 22 patients with BSG-IDH mut treated between January 2011 and January 2017.
- Collection and analysis of clinical, radiological, pathological, and survival data.
- Assessment of molecular markers including IDH1, TP53, MGMT promoter methylation, and AT-RX loss.
Main Results:
- The median age was 38.5 years, with a male predominance (63.6%).
- Common mutations included IDH1, TP53, and noncanonical IDH mutations (59.1%). MGMT promoter methylation (55.6%) and AT-RX loss (63.2%) were also frequent.
- Tumors often located in the pontine-medullary oblongata (54.5%) with ill-defined boundaries (68.2%), no T2-FLAIR mismatch (100%), and minimal contrast enhancement (86.3%).
- Median overall survival was 124.8 months, with 5-year survival at 54.5%. Recurrence occurred in 6 patients, with 2 progressing to WHO grade 4.
Conclusions:
- BSG-IDH mut represents a unique subgroup of brainstem gliomas with distinctive features.
- This subtype exhibits a more favorable prognosis compared to other brainstem gliomas.
- Further research is warranted to elucidate molecular mechanisms and optimize treatment strategies for BSG-IDH mut.
